Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division
June 07, 2023 at 06:37 pm IST
Share
Endonovo Therapeutics, Inc. is working with a prominent developer of telehealth (telemedicine) platforms to establish a new telehealth division for Endonovo. Telehealth services are a rapidly growing technology within the MedTech healthcare industry. The telehealth market has experienced a surge in growth as a result of the COVID-19 pandemic. According to a recent report by Reportlinker.com titled: "Global telehealth Industry", the global market for telehealth is projected to reach $723.3 billion by 2030, with a CAGR of 23% from 2022 to 2030. The software and services segment is expected to record a CAGR of 21.1%, reaching $462.8 billion by the end of the analysis period. The pandemic and recent expansion of medical services has served as a catalyst for telehealth growth as patients seek alternative ways to access healthcare services amid restrictions on in-person visits.
The rise of telehealth and digital health technologies has opened new opportunities for healthcare providers to improve patient healthcare access and reduce costs by reaching patients in remote or underserved areas. In the rapidly evolving landscape of healthcare, the integration of telehealth solutions presents opportunities to enhance access to medical services and improve patient outcomes. Endonovo's SofPulse Pulsed Electro Magnetic Field (PEMF) Therapy -- which can be used to treat pain and inflammation as a cost-effective and patient-friendly therapy can expand exponentially through telehealth direct to consumer sales. By leveraging the power of telecommunication and digital platforms, telehealth eliminates geographical barriers, bringing medical expertise directly to patients through virtual consultations, remote monitoring and personalized care plans. Patients will have the opportunity to call into the telehealth system and speak to an MD regarding a health condition that could be treated or have benefits in utilizing SofPulse® PEMF system. This transformative approach enhances convenience and affordability. It also provides tremendous potential to improve overall healthcare delivery, empower patients and drive positive outcomes ensuring that their healthcare needs are met effectively.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.